pharmaceutical development
Recently Published Documents


TOTAL DOCUMENTS

612
(FIVE YEARS 156)

H-INDEX

37
(FIVE YEARS 6)

Author(s):  
Alina Soloviova ◽  
Olha Kaliuzhnaia ◽  
Oksana Strilets ◽  
Dmytro Lytkin ◽  
Olga Goryacha

The aim. To conduct research on the pharmaceutical development of a complex preparation with probiotic “Probioskin” in the form of an emulgel for the treatment of infectious and inflammatory dermatological diseases. Methods. Uniformity was determined by visual inspection of the test samples using an XSP-128 ULAB biological microscope. The study of the rheological properties of the samples was carried out using a Rheolab QC rheovisosimeter (Anton Paar, Austria) using a system of coaxial cylinders C-CC27 / SS. Microbiological studies and biotesting on a biological model of ciliates were carried out in aseptic conditions of a laminar box (biological safety cabinet AC2-4E1 “Esco”, Indonesia) of the Department of Biotechnology of the National University of Pharmacy (completely). Pharmacological studies (determination of the parameters of acute toxicity and anti-inflammatory properties on the model of acute exudative inflammation of the foot in rats caused by zymosan and carrageenan) were carried out on the basis of the Central Research Laboratory of the NUPh. Results. On the basis of the complex of the carried out studies, the composition of the complex preparation for skin use “Probioskin” was substantiated. The analysis of the microbiological purity of the developed agent during the proposed shelf life of 12 months showed that the drug meets the requirements of the State Pharmacopoeia Monograph for cutaneous application in terms of the level of microbial contamination by foreign microflora. The complex of pharmacological studies carried out indicates that the drug “Probioskin” can be attributed to group 6 of class and classified as a “relatively harmless” agent. The study of the anti-inflammatory effect of the drug indicates that the drug exhibits moderate anti-inflammatory properties. Under the condition of zymosan inflammation, which is associated with the activation of leukotrienes as inflammatory mediators, the average antiexudative activity of the drug is 33 %. The drug has a moderate antiexudative effect under the condition of carrageenan edema, which is evidence of its effect on exudation processes mediated by prostaglandins. The mean AEA of the study drug was 24 %. Conclusions. For the development of a soft preparation for skin use for the treatment of infectious and inflammatory dermatological diseases, the following components have been selected: active – lactobacilli, dexpanthenol, lactic acid; auxiliary - propylene glycol, peach oil, polysorbate-80, aristophlex, tocopherol, the concentration of which was substantiated on the basis of a complex of organoleptic, physicochemical, pharmacological, microbiological and biological studies. It has been experimentally established that the “Probioskin” emulgel meets the requirements of the SPhU in terms of the level of microbial contamination by extraneous microflora. Pharmacological studies allow the drug to be classified as “relatively harmless” with anti-inflammatory properties at a level not lower than the reference drug


2021 ◽  
Author(s):  
Jiao Li ◽  
Chun-Lin Zhuang

The indole scaffold is one of the most important heterocyclic ring systems for pharmaceutical development, and serves as an active moiety in several clinical drugs. Fungi derived from marine origin are more liable to produce novel indole-containing natural products due to their extreme living environments. The indole alkaloids from marine fungi have drawn considerable attention for their unique chemical structures and significant biological activities. This review attempts to provide a summary of the structural diversity of marine fungal indole alkaloids including prenylated indoles, diketopiperazine indoles, bisindoles or trisindoles, quinazoline-containing indoles, indole-diterpenoids, and other indoles, as well as their known biological activities, mainly focusing on cytotoxic, kinase inhibitory, antiinflammatory, antimicrobial, anti-insecticidal, and brine shrimp lethal effects. A total of 306 indole alkaloids from marine fungi have been summarized, covering the references published from 1995 to early 2021, expecting to be beneficial for drug discovery in the future.


Author(s):  
Premadevi Kalmegh ◽  
Bharat Rathi ◽  
Renu Rathi ◽  
Poonam Madan

Introduction: Skin diseases are among the most common of all health illness in recent years, In Ayurveda, management of skin diseases includes internal and external administration. External administration includes various topical applications However, herbal medicines are not completely safe from adverse effects and develop irritation, rashes, redness and burning sensation on the skin as observed in recent researches.“Hence there is a requirement of a safe drug which should be economical & affordable for all. Hence present study is undertaken to study dermal toxicity profile Aargwadhadi oil and Aargwadhadi ointment in an experimental animal and make available safe and efficient drug to the human being. Aim and Objective: Pharmaceutical development, standardization and evaluation of acute, sub-acute dermal toxicity and efficacy of a Aargwadhadi oil and Aargwadhadi ointment and compare efficacy and safety of Aargwadhadi oil and Aargwadhadi ointment. Materials and Methods: Aargwadhadioil and Aargwadhadi Ointment will be prepared as per classical reference and it will be converted into ointment form. Analytical study for standardization of Aargwadhadi oil and Aargwadhadi ointment will be done.  Evaluation of Acute and sub-acute dermal toxicity study in experimental animals of both dosage forms as well, efficacy study of Aargwadhadi oil and Aargwadhadi ointment on animal model of vitiligo will be done. Observations and Results: Observation will be done on the basis of assessment criteria evaluation of control group and experimental group will be noted. Results will be drawn on the basis of observations and applying suitable tests. It will be noted and presented in form of table, charts, graphs etc. Conclusion: Conclusion of the study will be drawn accordingly from the recorded observations, analysis of data.


2021 ◽  
pp. 1411-1418
Author(s):  
Elena A. Bryzgalova-Plan ◽  
Marina V. Kovshova ◽  
Lidiya B. Larina ◽  
Irina O. Ryzhova ◽  
Svetlana N. Lobanova

2021 ◽  
pp. 1-8
Author(s):  
Andrey Nascimento ◽  
Evandro Araujo ◽  
Carlos Hagio ◽  
Silas Almeida ◽  
Ana Carolina Rodrigues ◽  
...  

Polymers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 3898
Author(s):  
Malaiporn Wongkaew ◽  
Pikulthong Chaimongkol ◽  
Noppol Leksawasdi ◽  
Kittisak Jantanasakulwong ◽  
Pornchai Rachtanapun ◽  
...  

Concerns regarding the overconsumption of natural resources has provoked the recovery of biopolymers from food processing biomass. Furthermore, the current market opportunity for pectin in other areas has increased, necessitating the search for alternative pectin resources. This is also a step towards the sustainable and circular green economy. Mango peel is the byproduct of agro-processing and has been used for high value-added components such as polysaccharide biopolymers. Pectin derived from the peel is yet to be exploited to its greatest extent, particularly in terms of its separation and physiochemical properties, which limit its applicability to dietary fiber in culinary applications. The functionality of the mango peel pectin (MPP) strongly depends on the molecular size and degree of esterification which highlight the importance of isolation and characterisation of pectin from this novel resource. This article therefore provides a useful overview of mango peel as a potential biomaterial for the recovery of MPP. Different extraction techniques and the integrated recovery were also discussed. The utilisation of MPP in different industrial schemes are also detailed out from different perspectives such as the pharmaceutical and biotechnology industries. This review convincingly expresses the significance of MPP, providing a sustainable opportunity for food and pharmaceutical development.


Nanomaterials ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 3018
Author(s):  
Kyle M. Pierce ◽  
William R. Miklavcic ◽  
Kyle P. Cook ◽  
Mikayla Sweitzer Hennen ◽  
Kenneth W. Bayles ◽  
...  

While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncolytic bacteria over the last 20 years of research towards clinical translation and acceptance as novel cancer therapeutics are compared. Novel nanoparticle, oncolytic virus, and oncolytic bacteria therapies all start with a common goal of accomplishing therapeutic drug activity or delivery to a specific site while avoiding off-target effects, with overlapping methodology between all three modalities. Indeed, the degree of overlap is substantial enough that breakthroughs in one therapeutic could have considerable implications on the progression of the other two. Each oncotherapeutic modality has accomplished clinical translation, successfully overcoming the potential pitfalls promising therapeutics face. However, once studies enter clinical trials, the data all but disappears, leaving pre-clinical researchers largely in the dark. Overall, the creativity, flexibility, and innovation of these modalities for solid tumor treatments are greatly encouraging, and usher in a new age of pharmaceutical development.


2021 ◽  
Vol 76 (4) ◽  
pp. 351-360
Author(s):  
Elena O. Bakhrushina ◽  
Maria N. Anurova ◽  
Andrey V. Aleshkin ◽  
Natalia B. Demina ◽  
Ivan I. Krasnyuk ◽  
...  

The article discusses the main uses of bacteriophages as an alternative or supplement to antibiotic therapy. The authors characterize the drugs of bacteriophages and perfume and cosmetic products containing bacteriophages presented on the pharmaceutical market of the Russian Federation. Prospects and algorithms for the extemporal manufacture of medicinal forms with bacteriophages for personalized therapy, developed in countries of Europe, USA, China, Russian Federation are considered. The analysis of scientific publications on the main international databases shows the interest of the developers in the problem of the creation of new bacteriophages preparations with stable titer in different medicinal forms for routes of medication administration. One of the problems of pharmaceutical development of such products is the insufficient regulatory framework. It was noted that for the first time in the State Pharmacopoeia of the Russian Federation a general pharmacopaedic article Bacteriophages medicinal-prophylactic and private pharmacopaedic articles about the main bacteriophages and their cocktails produced by the Russian industry were introduced. It has been shown that expansion of the range of medicinal forms and ways of introducing bacteriophages, extemporal manufacture of effective and stable preparations along with their industrial production an attainable task.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1617
Author(s):  
Luigi Battaglia ◽  
Anna Scomparin ◽  
Chiara Dianzani ◽  
Paola Milla ◽  
Elisabetta Muntoni ◽  
...  

Cutaneous melanoma is one of the most aggressive solid tumors, with a low survival for the metastatic stage. Currently, clinical melanoma treatments include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. Of note, innovative therapeutic regimens concern the administration of multitarget drugs in tandem, in order to improve therapeutic efficacy. However, also, if this drug combination is clinically relevant, the patient’s response is not yet optimal. In this scenario, nanotechnology-based delivery systems can play a crucial role in the clinical treatment of advanced melanoma. In fact, their nano-features enable targeted drug delivery at a cellular level by overcoming biological barriers. Various nanomedicines have been proposed for the treatment of cutaneous melanoma, and a relevant number of them are undergoing clinical trials. In Italy, researchers are focusing on the pharmaceutical development of nanoformulations for malignant melanoma therapy. The present review reports an overview of the main melanoma-addressed nanomedicines currently under study in Italy, alongside the state of the art of melanoma therapy. Moreover, the latest Italian advances concerning the pre-clinical evaluation of nanomedicines for melanoma are described.


Sign in / Sign up

Export Citation Format

Share Document